Lazard Asset Management
KYMR icon

Lazard Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Lazard Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,664
Closed -$116K – 2091
2025
Q2 		$116K Buy
+2,664
New +$91.7K ﹤0.01% 1840
2024
Q3 		– Sell
-2,856
Closed -$84K – 2370
2024
Q2 		$84K Buy
+2,856
New +$98.9K ﹤0.01% 1803
2022
Q1 		– Sell
-1,238
Closed -$78K – 2430
2021
Q4 		$78K Buy
+1,238
New +$72.1K ﹤0.01% 1535
2021
Q3 		– Sell
-1,512
Closed -$73K – 2224
2021
Q2 		$73K Buy
+1,512
New +$65.6K ﹤0.01% 1440

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Lazard Asset Management's KYMR Position: Q3 2025 in Review

Lazard Asset Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 2,664 shares — an estimated $116K sold.

Lazard Asset Management first reported a position in KYMR in Q2 2021 and held it in 4 quarters. The position peaked at $116K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Lazard Asset Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,664 Kymera Therapeutics shares in Q3 2025, an estimated $116K.
  • Lazard Asset Management first reported a position in Kymera Therapeutics in Q2 2021 and held it in 4 quarters.
  • Lazard Asset Management's Kymera Therapeutics position peaked at $116K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.